Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3

Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival (PFS), adding to evidence that the off-the-shelf treatment can match the eff Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival, adding to evidence that the off-the-shelf treatment can match the efficacy of autologous products in lymphoma patients. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards…

Source: FierceBiotech